Litcius/Paper detail

Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations

Xile Liu, Lu Zhang, Haiwen Wan, Zhenzhen Zhu, Jing Jin, Yuxin Qin, Weifeng Mao, Kang Yan, Douglas D. Fang, Wen Jiang, Lihong Hu, Jinhua Chen, Kevin Chen, Shu‐Hui Chen, Jian Li, Shuyong Zhao, Shansong Zheng, Long Zhang, Charles Z. Ding

2022Bioorganic & Medicinal Chemistry Letters15 citationsDOIOpen Access PDF

Topics & Concepts

CrizotinibChemistryALK inhibitorCancer researchMutantGeneBiologyLung cancerMedicineBiochemistryOncologyMalignant pleural effusionLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer therapeutics and mechanisms
Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations | Litcius